Can genomics bend the cost curve?

JAMA

Volumn 307, Issue 10, 2012, Pages 1031-1032

  Armstrong, Katrina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG COST; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC VARIABILITY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTO ONCOGENE; RECEPTOR GENE; RISK ASSESSMENT; SHORT SURVEY; ARTICLE; BREAST TUMOR; ECONOMICS; FEMALE; GENETIC SCREENING; GENETICS; GENOMICS; HEALTH CARE DELIVERY; MEDICAL TECHNOLOGY; PATIENT CARE PLANNING; STANDARD; UNITED STATES;

BIOMEDICAL TECHNOLOGY; BREAST NEOPLASMS; COST CONTROL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; GENE EXPRESSION PROFILING; GENETIC TESTING; GENOMICS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; PATIENT CARE PLANNING; UNITED STATES;

EID: 84858249883     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.261     Document Type: Short Survey

References (8)

1. Brook RH. Can the Patient-Centered Outcomes Research Institute become relevantto controlling medical costs and improving value? JAMA. 2011;306(18):2020-2021.
2. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364(4):340-350.
3. Bodenheimer T. High and rising health care costs: part 2, technologic innovation. Ann Intern Med. 2005;142(11):932-937. (Pubitemid 40791809)
4. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol. 2007;25(6):611-613. (Pubitemid 350002913)
5. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734. (Pubitemid 46622311)
6. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28(10):1671-1676.
7. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109(6):1011-1018. (Pubitemid 46435378)
8. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011; 3(111):111ra121.